Recruiting

Osteosarcoma

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT06064682

Conditions

Osteosarcoma

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

standard of care biopsy

standard of care biopsy

Study Details

Brief summary:

The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.

Conditions

Osteosarcoma

Study ID

NCT06064682

Start date

Feb 12, 2024

Status verified date

May, 2026

Completion date

Jan 1, 2028

Anticipated

Primary completion date

Jan 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion / exclusion criteria - Group1:

\- Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes

Inclusion / exclusion criteria - Group 2:

\- Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes

Study Design

Enrollment

40 participants

Anticipated

Interventions and Outcome Measures

Arms

Group 1: local tumor

patients with localized osteosarcoma who are scheduled to undergo diagnostic biopsy and are planned for surgical excision of the primary tumor

Group 2: metastatic disease

patients with metastatic osteosarcoma who are scheduled to undergo either biopsy or surgery of metastatic disease

Interventions

standard of care biopsy

Image-guided or surgical biopsy of the lesion that is suspected to be osteosarcoma in a patient with localized disease (Group 1)

standard of care biopsy

Image-guided or surgical biopsy or excision of the lesion that is suspected to be recurrent or metastatic osteosarcoma (Group 2).

Primary outcome measure

  • organoids from initial biopsy [ Time Frame: two years ]

Central Contacts and Locations

Central contacts

Summer Swearingen

(424) 766-9349SSwearingen@mednet.ucla.edu

Locations

UCLA / Jonsson Comprehensive Cancer Center

Recruiting

Los Angeles, California, United States, 90095

Contacts

Summer Swearingen

424-766-9349SSwearingen@mednet.ucla.edu

More Information

Sponsor

Jonsson Comprehensive Cancer Center

Last update posted

May 11, 2026

Last verified

May, 2026

Keywords

  • Osteosarcoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center on 2026-05-11.